Company intelligence / Profile preview

Evo Plant

Ownership: Private
Development stage: Preclinical

Overview

EvoBiotech develops a novel technology platform using plant-derived extracellular vesicles for regenerative medicine. Their work leverages the unique properties of these vesicles to promote healing in damaged tissues. The company has strong expertise in engineering and purifying these vesicles but has not reported clinical trial results yet.

Therapeutic areas: OtherCardiovascularImmunology
Modalities: Extracellular vesicle therapyPlant-derived extracellular vesiclesPotentially drug delivery platform
Industry: Biotech

Partnerships

None publicly disclosed

Beyond the preview

Go deeper on Evo Plant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evo Plant.

Explore the full profile